APTOF · Aptose Biosciences Inc. · Insider Trading
Substantial doubt about the company's ability to continue as a going concern.
“The aforementioned conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed May 13, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-30 | PLATZER ERICH |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Stock Option (Right to Buy)
|
3,333 |
| 2026-06-30 | Rice William G. |
Director, Chair, President & CEO |
Other↓
Filing footnotes — Common Shares (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Common Shares
|
400,000 |
| 2026-06-30 | BURGER DENIS R |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Stock Option (Right to Buy)
|
50,000 |
| 2026-06-30 | Vincent Mark D. |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd, a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Stock Option (Right to Buy)
|
50,000 |
| 2026-06-30 | BURGER DENIS R |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Stock Option (Right to Buy)
|
100,000 |
| 2026-06-30 | Whitehead Warren |
Director |
Other↓
Filing footnotes — Stock Options (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Stock Options (Right to Buy)
|
40,000 |
| 2026-06-30 | Rice William G. |
Director, Chair, President & CEO |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Employee Stock Option (Right to Buy)
|
300,000 |
| 2026-06-30 | Whitehead Warren |
Director |
Other↓
Filing footnotes — Director Option Grant (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Option Grant
|
152,500 |
| 2026-06-30 | Seizinger Bernd R. |
Director |
Other↓
Filing footnotes — Stock Option (right to buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean Corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on second anniversary of the grant date. |
Stock Option (right to buy)
|
100,000 |
| 2026-06-30 | Vincent Mark D. |
Director |
Other↓
Filing footnotes — Director Option Grant (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd, a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Option Grant
|
154,000 |
| 2026-06-30 | BURGER DENIS R |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Stock Option (Right to Buy)
|
5,000 |
| 2026-06-30 | Vincent Mark D. |
Director |
Other↓
Filing footnotes — Director Option Grant (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd, a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Option Grant
|
50,000 |
| 2026-06-30 | Rice William G. |
Director, Chair, President & CEO |
Other↓
Filing footnotes — Stock Options (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Stock Options (Right to Buy)
|
400,000 |
| 2026-06-30 | BURGER DENIS R |
Director |
Other↓
Filing footnotes — Stock Options (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Stock Options (Right to Buy)
|
40,000 |
| 2026-06-30 | Payne Fletcher |
Sr VP and CFO |
Other↓
Filing footnotes — Common Shares (Indirect)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc. whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00. |
Common Shares
(I)
|
22 |
| 2026-06-30 | Whitehead Warren |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Stock Option (Right to Buy)
|
50,000 |
| 2026-06-30 | Bejar Rafael |
Sr VP & Chief Medical Officer |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Employee Stock Option (Right to Buy)
|
35,000 |
| 2026-06-30 | Whitehead Warren |
Director |
Other↓
Filing footnotes — Director Option Grant (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Option Grant
|
100,000 |
| 2026-06-30 | Rice William G. |
Director, Chair, President & CEO |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Employee Stock Option (Right to Buy)
|
100,000 |
| 2026-06-30 | Whitehead Warren |
Director |
Other↓
Filing footnotes — Director Option Grant (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Option Grant
|
50,000 |
| 2026-06-30 | Vincent Mark D. |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd, a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Stock Option (Right to Buy)
|
10,000 |
| 2026-06-30 | Bejar Rafael |
Sr VP & Chief Medical Officer |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Employee Stock Option (Right to Buy)
|
343,000 |
| 2026-06-30 | Whitehead Warren |
Director |
Other↓
Filing footnotes — Director Option Grant (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Option Grant
|
50,000 |
| 2026-06-30 | Rice William G. |
Director, Chair, President & CEO |
Other↓
Filing footnotes — Warrants (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. |
Warrants
|
50,000 |
| 2026-06-30 | Vincent Mark D. |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd, a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Stock Option (Right to Buy)
|
100,000 |
| 2026-06-30 | PLATZER ERICH |
Director |
Other↓
Filing footnotes — Director Option Grant (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Option Grant
|
135,000 |
| 2026-06-30 | Bejar Rafael |
Sr VP & Chief Medical Officer |
Other↓
Filing footnotes — Employee Option Grant (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Employee Option Grant
|
200,000 |
| 2026-06-30 | PLATZER ERICH |
Director |
Other↓
Filing footnotes — Common Shares (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00. |
Common Shares
|
1,122 |
| 2026-06-30 | Rice William G. |
Director, Chair, President & CEO |
Other↓
Filing footnotes — Performance Stock Options (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Performance Stock Options
|
600,000 |
| 2026-06-30 | PLATZER ERICH |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Stock Option (Right to Buy)
|
50,000 |
| 2026-06-30 | Bejar Rafael |
Sr VP & Chief Medical Officer |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Employee Stock Option (Right to Buy)
|
400,000 |
| 2026-06-30 | Seizinger Bernd R. |
Director |
Other↓
Filing footnotes — Stock Option (right to buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean Corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on second anniversary of the grant date. |
Stock Option (right to buy)
|
50,000 |
| 2026-06-30 | Seizinger Bernd R. |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean Corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on second anniversary of the grant date. |
Director Stock Option (Right to Buy)
|
3,333 |
| 2026-06-30 | Bejar Rafael |
Sr VP & Chief Medical Officer |
Other↓
Filing footnotes — Performance Stock Option (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Performance stock options subject to specific performance criteria. |
Performance Stock Option
|
400,000 |
| 2026-06-30 | Rice William G. |
Director, Chair, President & CEO |
Other↓
Filing footnotes — Employee Option Grant (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Employee Option Grant
|
700,000 |
| 2026-06-30 | Vincent Mark D. |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd, a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Stock Option (Right to Buy)
|
3,333 |
| 2026-06-30 | BURGER DENIS R |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Stock Option (Right to Buy)
|
3,333 |
| 2026-06-30 | Rice William G. |
Director, Chair, President & CEO |
Other↓
Filing footnotes — Common Shares (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00. |
Common Shares
|
613,252 |
| 2026-06-30 | Whitehead Warren |
Director |
Other↓
Filing footnotes — Common Shares (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00. |
Common Shares
|
33 |
| 2026-06-30 | Bejar Rafael |
Sr VP & Chief Medical Officer |
Other↓
Filing footnotes — Common Shares (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00. |
Common Shares
|
244 |
| 2026-06-30 | Payne Fletcher |
Sr VP and CFO |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc. whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of the grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Employee Stock Option (Right to Buy)
|
200,000 |
| 2026-06-30 | Payne Fletcher |
Sr VP and CFO |
Other↓
Filing footnotes — Common Shares (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc. whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00. |
Common Shares
|
222 |
| 2026-06-30 | Whitehead Warren |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Stock Option (Right to Buy)
|
53,000 |
| 2026-06-30 | Vincent Mark D. |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd, a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Stock Option (Right to Buy)
|
5,000 |
| 2026-06-30 | PLATZER ERICH |
Director |
Other↓
Filing footnotes — Director Stock Option (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Stock Option
|
10,000 |
| 2026-06-30 | Payne Fletcher |
Sr VP and CFO |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc. whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of the grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Employee Stock Option (Right to Buy)
|
55,000 |
| 2026-06-30 | Bejar Rafael |
Sr VP & Chief Medical Officer |
Other↓
Filing footnotes — Employee Stock Option (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Employee Stock Option
|
200,000 |
| 2026-06-30 | BURGER DENIS R |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share. Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Stock Option (Right to Buy)
|
10,000 |
| 2026-06-30 | PLATZER ERICH |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Stock Option (Right to Buy)
|
100,000 |
| 2026-06-30 | PLATZER ERICH |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Director Stock Option (Right to Buy)
|
50,000 |